JZP-110: Completed Phase III enrollment

Jazz completed enrollment of about 440 patients in the double-blind, placebo-controlled Phase II 14-003 trial evaluating 37.5, 75, 150 and 300 mg oral JZP-110 once daily. In 2014, Jazz purchased from ...